Limits...
Efficacy of combination therapy with sitagliptin and low-dose glimepiride in Japanese patients with type 2 diabetes.

Ishii H, Ohkubo Y, Takei M, Nishio S, Yamazaki M, Kumagai M, Sato Y, Suzuki S, Aoki Y, Miyamoto T, Kakizawa T, Sakuma T, Komatsu M - J Clin Med Res (2014)

Bottom Line: The dose of glimepiride was reduced to 1 mg/day and 50 mg/day of sitagliptin was added without changing the doses of any other antihyperglycemic agents.In the low-dose group, 8.1 ± 0.2% decreased to 7.0 ± 0.1%; in the high-dose group, 8.4 ± 0.1% decreased to 7.3 ± 0.2%.The time course of the degree of HbA1c reduction in the high-dose group was almost superimposable on that in the low-dose group.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine, Division of Diabetes, Endocrinology and Metabolism, Shinshu University School of Medicine, Japan.

ABSTRACT

Background: We examined the effects of combination therapy with 50 mg/day of sitagliptin and low-dose glimepiride (1 mg/day) in patients with type 2 diabetes.

Methods: Twenty-six patients with poorly controlled type 2 diabetes currently taking high-dose glimepiride (≥ 2 mg/day) were enrolled in the study. The dose of glimepiride was reduced to 1 mg/day and 50 mg/day of sitagliptin was added without changing the doses of any other antihyperglycemic agents. The patients were divided into two groups: the low-dose group (2 or 3 mg glimepiride decreased to 1 mg: n = 15) and the high-dose group (4 or 6 mg glimepiride decreased to 1 mg: n = 11).

Results: Combination therapy significantly lowered HbA1c after 24 weeks of treatment in both groups. In the low-dose group, 8.1 ± 0.2% decreased to 7.0 ± 0.1%; in the high-dose group, 8.4 ± 0.1% decreased to 7.3 ± 0.2%. The time course of the degree of HbA1c reduction in the high-dose group was almost superimposable on that in the low-dose group. There were no changes in body weight and no hypoglycemia and in either group during the study period. In conclusion, our results suggested that the combination therapy used in the study is both well tolerated and effective.

Conclusion: This study indicated the usefulness of dipeptidyl peptidase (DPP)-4 inhibitors in Japanese patients with type 2 diabetes, and also reinforces the importance of low doses of sulfonylurea for effective glycemic management.

No MeSH data available.


Related in: MedlinePlus

Changes in HbA1c for 48 weeks. Actual mean values of HbA1c in two groups are shown. The values are mean ± SEM. A statistical analysis was performed by Paired t-test.* *P < 0.01 vs. 0 week.
© Copyright Policy - open access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3935521&req=5

Figure 4: Changes in HbA1c for 48 weeks. Actual mean values of HbA1c in two groups are shown. The values are mean ± SEM. A statistical analysis was performed by Paired t-test.* *P < 0.01 vs. 0 week.

Mentions: All patients continued the treatment for 48 weeks with the same medication except in 4 cases; 1 patient required an increase in glimepiride dose to 2 mg/day and 3 patients required an increase in sitagliptin dose to 100 mg/day. The time courses of changes in HbA1c for 48 weeks are shown in Figure 4. These observations indicated that the efficacy of combination therapy lasted for 48 weeks.


Efficacy of combination therapy with sitagliptin and low-dose glimepiride in Japanese patients with type 2 diabetes.

Ishii H, Ohkubo Y, Takei M, Nishio S, Yamazaki M, Kumagai M, Sato Y, Suzuki S, Aoki Y, Miyamoto T, Kakizawa T, Sakuma T, Komatsu M - J Clin Med Res (2014)

Changes in HbA1c for 48 weeks. Actual mean values of HbA1c in two groups are shown. The values are mean ± SEM. A statistical analysis was performed by Paired t-test.* *P < 0.01 vs. 0 week.
© Copyright Policy - open access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3935521&req=5

Figure 4: Changes in HbA1c for 48 weeks. Actual mean values of HbA1c in two groups are shown. The values are mean ± SEM. A statistical analysis was performed by Paired t-test.* *P < 0.01 vs. 0 week.
Mentions: All patients continued the treatment for 48 weeks with the same medication except in 4 cases; 1 patient required an increase in glimepiride dose to 2 mg/day and 3 patients required an increase in sitagliptin dose to 100 mg/day. The time courses of changes in HbA1c for 48 weeks are shown in Figure 4. These observations indicated that the efficacy of combination therapy lasted for 48 weeks.

Bottom Line: The dose of glimepiride was reduced to 1 mg/day and 50 mg/day of sitagliptin was added without changing the doses of any other antihyperglycemic agents.In the low-dose group, 8.1 ± 0.2% decreased to 7.0 ± 0.1%; in the high-dose group, 8.4 ± 0.1% decreased to 7.3 ± 0.2%.The time course of the degree of HbA1c reduction in the high-dose group was almost superimposable on that in the low-dose group.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine, Division of Diabetes, Endocrinology and Metabolism, Shinshu University School of Medicine, Japan.

ABSTRACT

Background: We examined the effects of combination therapy with 50 mg/day of sitagliptin and low-dose glimepiride (1 mg/day) in patients with type 2 diabetes.

Methods: Twenty-six patients with poorly controlled type 2 diabetes currently taking high-dose glimepiride (≥ 2 mg/day) were enrolled in the study. The dose of glimepiride was reduced to 1 mg/day and 50 mg/day of sitagliptin was added without changing the doses of any other antihyperglycemic agents. The patients were divided into two groups: the low-dose group (2 or 3 mg glimepiride decreased to 1 mg: n = 15) and the high-dose group (4 or 6 mg glimepiride decreased to 1 mg: n = 11).

Results: Combination therapy significantly lowered HbA1c after 24 weeks of treatment in both groups. In the low-dose group, 8.1 ± 0.2% decreased to 7.0 ± 0.1%; in the high-dose group, 8.4 ± 0.1% decreased to 7.3 ± 0.2%. The time course of the degree of HbA1c reduction in the high-dose group was almost superimposable on that in the low-dose group. There were no changes in body weight and no hypoglycemia and in either group during the study period. In conclusion, our results suggested that the combination therapy used in the study is both well tolerated and effective.

Conclusion: This study indicated the usefulness of dipeptidyl peptidase (DPP)-4 inhibitors in Japanese patients with type 2 diabetes, and also reinforces the importance of low doses of sulfonylurea for effective glycemic management.

No MeSH data available.


Related in: MedlinePlus